Abstract: a signal generator comprising a timer configured to execute a predetermined session N times upon detecting a pulse of a first trigger signal and to output a signal generation start signal having one or more pulses in each said session, and a channel signal generation unit configured to generate a timing signal having one or more pulses upon detecting a pulse of the signal generation start signal.

Abstract: Provided is a mobile terminal and method for controlling a sound (audio) to be output, the mobile terminal including at least one application including sound (audio) data and requesting an output sound, a sound (audio) control unit to determine an output sound when a plurality of requests for the output sound is input by a plurality of applications being executed, and a sound (audio) output unit to output the determined sound by forming a virtual output path for each of the sound data to be output, and blocking other virtual output paths aside from a virtual output path mapped to the sound determined to be output by the sound control unit.

Abstract: Provided is a mobile terminal and method for controlling a sound (audio) to be output, the mobile terminal including at least one application including sound (audio) data and requesting an output sound, a sound (audio) control unit to determine an output sound when a plurality of requests for the output sound is input by a plurality of applications being executed, and a sound (audio) output unit to output the determined sound by forming a virtual output path for each of the sound data to be output, and blocking other virtual output paths aside from a virtual output path mapped to the sound determined to be output by the sound control unit.

Abstract: Provided is a mobile terminal and method for controlling a sound (audio) to be output, the mobile terminal including at least one application including sound (audio) data and requesting an output sound, a sound (audio) control unit to determine an output sound when a plurality of requests for the output sound is input by a plurality of applications being executed, and a sound (audio) output unit to output the determined sound by forming a virtual output path for each of the sound data to be output, and blocking other virtual output paths aside from a virtual output path mapped to the sound determined to be output by the sound control unit.

Abstract: Provided is a mobile terminal and method for controlling a sound (audio) to be output, the mobile terminal including at least one application including sound (audio) data and requesting an output sound, a sound (audio) control unit to determine an output sound when a plurality of requests for the output sound is input by a plurality of applications being executed, and a sound (audio) output unit to output the determined sound by forming a virtual output path for each of the sound data to be output, and blocking other virtual output paths aside from a virtual output path mapped to the sound determined to be output by the sound control unit.

Abstract: An apparatus and method for controlling access to a network in portable terminal based on a characteristic of an application may determine the characteristic of the application based on at least one of a reference security level of the application, a reference data amount of the application, and a reference speed of the application, and may select a network to be connected to from among available networks based on the characteristic of the application when executing the application.

Abstract: The invention provides 4-IBBL blocking agents, as well as pharmaceutical compositions and articles of manufacture comprising such blocking agents as new therapeutic interventions for sustained inflammation. Thus, the invention also provides methods for reducing sustained production of tumor necrosis factor.

Abstract: The present invention relates to humanized monoclonal antibodies LB-00503 and LB-00506, which are specific for human 4-1BB molecules, have high binding affinities and can bind efficiently with activated T cells expressing the 4-1BB molecule, as well as pharmaceutical compositions. Particularly, the present invention provides said humanized antibody LB-00503, which is modified from the humanized antibody Hz4B4-2 and substitutes the 61st amino acid, serine by asparagine in the amino acid residues of 59th˜61st and said humanized antibody LB-00506, which enhances the antibody binding affinity of said humanized antibody LB-00503 in which 2 amino acid residues of the right border in the antibody binding site CDR2 of the heavy chain variable region are substituted from glutamine (Q)—glycine (G) to lysine (K)—serine (S).

Abstract: The present invention is directed to humanized antibodies that specifically bind the protein 4-1BB. The antibodies can be made by grafting of the complementarity determining regions (CDR's) of mouse monoclonal antibody to human 4-1BB to the remaining portions of a human antibody and by making further amino acid replacements. In addition, a pharmaceutical composition that includes the humanized antibody can be made and can be used to treat autoimmune diseases to suppress an immune response. The humanized antibody of the invention has high affinity for human 4-1BB, and exhibits sequence similarity to human antibody. As a result, the pharmaceutical composition of the present invention can be used to treat autoimmune disease and act as an immunosuppressant in humans without much side-effect.